Log in

Relevant bibliographies by topics / Pricing of medicines / Journal articles

To see the other types of publications on this topic, follow the link: Pricing of medicines.

Journal articles on the topic 'Pricing of medicines'

Author: Grafiati

Published: 28 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pricing of medicines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ніженковська, І. В., М. М. Бабенко, Л. О. Гала, Н. В. Шолойко, and Н. О. Дацюк. "Analysis of access to medicines for the population by the state budget in Ukraine." Farmatsevtychnyi zhurnal, no. 5 (October 27, 2023): 3–10. http://dx.doi.org/10.32352/0367-3057.5.23.01.

Full text

Abstract:

The price of medicines is an important factor in ensuring accessibility for the population in the healthcare. Ukraine actively implements pricing policies in the healthcare in accordance with the recommendations of the World Health Organization (WHO). WHO recommendations aim to achieve two important objectives. First, they seek to ensure the availability of effective medicines for the population so that every patient has the opportunity to receive necessary treatment. Second, it is to create conditions for pharmaceutical companies to have incentives to continue their innovative activities in t

APA, Harvard, Vancouver, ISO, and other styles

2

Alrasheedy, Alian A. "Pharmaceutical pricing policy in Saudi Arabia: findings and implications." Generics and Biosimilars Initiative Journal 9, no. 1 (2020): 14–21. http://dx.doi.org/10.5639/gabij.2020.0901.003.

Full text

Abstract:

Introduction: Many countries have introduced policies and strategies to limit pharmaceutical expenditures. These include pharmaceutical pricing policies and related strategies to control medicine prices and to ensure appropriate and stable prices. The aim of this study was to provide an overview of the current pharmaceutical pricing policy for medicines in Saudi Arabia and to provide an evaluation of the impact of this policy on medicine prices. Methods: A description of the current pharmaceutical policy is presented by reviewing the current official documents and regulations related to pharma

APA, Harvard, Vancouver, ISO, and other styles

3

Van Den Berg, Sibren, Marcel Canoy, Lonneke Timmers, and Carla Hollak. "PP152 The Assessment Of The Price Of A Medicine: The Possible Application Of Cost-Based Pricing Methods." International Journal of Technology Assessment in Health Care 38, S1 (2022): S89—S90. http://dx.doi.org/10.1017/s0266462322002641.

Full text

Abstract:

IntroductionBefore admission to the insured package, the price of a medicine is usually assessed on the basis of the value of the medicine for the patient: the effect size on health and survival must be in line with the costs. That seems like a fair starting point, but the use of such ‘value-driven’ models sometimes results in unrealistic prices. These prices in turn lead to discussions about limitations within the healthcare budget and may result in delays in the accessibility of medicines. The aim of this study was to review several alternative pricing models and propose possible application

APA, Harvard, Vancouver, ISO, and other styles

4

Tiriveedhi, Venkataswarup. "Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis." Journal of Personalized Medicine 8, no. 4 (2018): 36. http://dx.doi.org/10.3390/jpm8040036.

Full text

Abstract:

The pricing of targeted medicines continues to be a major area of contention in healthcare economics. This issue is further complicated by redefining the role of molecular testing in precision medicine. Currently, whilst pricing of clinical laboratory diagnostics is cost-based, drug pricing is value-based. The pricing for molecular testing is under pressure to change the traditional business model, for it has a critical subsidiary role in determining the final value of targeted medicines. The market size for drugs is reduced by molecular testing when patients with the same disease are stratifi

APA, Harvard, Vancouver, ISO, and other styles

5

Bangalee, Varsha, and Fatima Suleman. "A Comparative Study on Medicine Pricing in Brazil, Russia, India, China and South Africa (BRICS)." Global Journal of Health Science 10, no. 10 (2018): 152. http://dx.doi.org/10.5539/gjhs.v10n10p152.

Full text

Abstract:

BACKGROUND: It is well documented that high prices hinder access to medicines to a large percentage of the population in low- and middle-income countries. It is with this in mind that governments have made attempts to control medicine pricing with the intent to protect and promote a country&rsquo;s overall health. BRICS as Brazil, Russia, India, China and South Africa have collectively become to be known, represent five newly emerging global economies, each one attempting to control medicine pricing and improve accessibility.   OBJECTIVE: To compare the medicine pricing regulat

APA, Harvard, Vancouver, ISO, and other styles

6

Kucherenko, L. I., I. V. Nizhenkovska, N. V. Sholoiko, L. O. Hala, and N. O. Datsiuk. "External reference pricing for medicines in Ukraine: latest trends." Current issues in pharmacy and medicine: science and practice 16, no. 3 (2023): 272–76. http://dx.doi.org/10.14739/2409-2932.2023.3.287758.

Full text

Abstract:

Compared to the previous year, the share of healthcare expenditure in the state budget of Ukraine has decreased, which is associated with increased funding for the security and defense sector. In terms of gross domestic product, healthcare spending has reduced to 2.8 %, which corresponds to the figures for 2019. These circumstances indicate the importance of proper budget utilization, including effectively regulating medicine prices. One of the key elements of rational healthcare budget usage is the development and implementation of external reference pricing (ERP). A well-formulated and imple

APA, Harvard, Vancouver, ISO, and other styles

7

Gandjour, Afschin. "Value-based pricing of add-on life-extending medicines based on economic evaluation." British Journal of Healthcare Management 29, no. 8 (2023): 1–7. http://dx.doi.org/10.12968/bjhc.2022.0031.

Full text

Abstract:

Value-based pricing of new medicines, when defined as pricing or reimbursement based on economic evaluation, requires the use of a threshold incremental cost-effectiveness ratio. Value-based pricing can leave little room for setting a price above zero for manufacturers of new life-extending add-on medicines that are used in combination regimens. This study aimed to present and explore different methodological approaches for pricing life-extending add-on medicines in this value-based pricing framework. The analysis demonstrated that excluding the costs of background therapy will create opportun

APA, Harvard, Vancouver, ISO, and other styles

8

Dylst, Pieter, Arnold Vulto, and Steven Simoens. "Overcoming challenges in market access of generic medicines in the European Union." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 9, no. 1 (2012): 21–28. http://dx.doi.org/10.1177/1741134312441107.

Full text

Abstract:

Generic medicines have become essential contributors for governments in their effort to contain public health care budgets. Therefore, market access of generic medicines should be made possible immediately after expiry of the patent protecting the originator medicine. Generic medicines can only enter the market when the patent on the originator medicine is expired and when a marketing authorisation and pricing and reimbursement approval have been obtained from the national competent authorities. Arguments on patent validity or patent infringement which result in litigation before national cour

APA, Harvard, Vancouver, ISO, and other styles

9

Koduah, Augustina, Leonard Baatiema, Irene A. Kretchy, et al. "Powers, engagements and resultant influences over the design and implementation of medicine pricing policies in Ghana." BMJ Global Health 7, no. 5 (2022): e008225. http://dx.doi.org/10.1136/bmjgh-2021-008225.

Full text

Abstract:

IntroductionUniversal availability and affordability of essential medicines are determined by effective design and implementation of relevant policies, typically involving multiple stakeholders. This paper examined stakeholder engagements, powers and resultant influences over design and implementation of four medicines pricing policies in Ghana: Health Commodity Supply Chain Master Plan, framework contracting for high demand medicines, Value Added Tax (VAT) exemptions for selected essential medicines, and ring-fencing medicines for local manufacturing.MethodsData were collected using reviews o

APA, Harvard, Vancouver, ISO, and other styles

10

Shankar, P. R., P. Subish, P. Mishra, and M. Lalit. "Ambiguous pricing of Nepalese medicines." Journal of Institute of Medicine Nepal 28, no. 3 (2006): 35–38. http://dx.doi.org/10.59779/jiomnepal.262.

Full text

Abstract:

Background: The National Drug Policy of Nepal aims to make the country self-reliant in drug production. Nepal follows a competitive market system where both domestic and foreign manufacturers compete. Previous studies had shown ambiguities in drug pricing. Recent studies are lacking. Hence the present study was carried out to obtain information on the price variation between Nepalese brands for different drugs. Methods:The prices of drugs listed in the December 2005 issue of Nepal Drug Review were analysed. The following formula was used for calculation. Percentage price variation = Price of m

APA, Harvard, Vancouver, ISO, and other styles

11

Vasan, Ashwin, and Jim Yong Kim. "Essential medicines pricing—reform needed." Lancet 373, no. 9659 (2009): 191–93. http://dx.doi.org/10.1016/s0140-6736(08)61763-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Kianzad, B. "Towards Fair Pricing of Medicines?" European Health & Pharmaceutical Law Review 6, no. 1 (2022): 3–23. http://dx.doi.org/10.21552/ehpl/2022/1/4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Anggriani, Yusi. "The Role of Medicine Pricing Policy for Improving the Affordability of Medicines." JURNAL ILMU KEFARMASIAN INDONESIA 16, no. 2 (2018): 172. http://dx.doi.org/10.35814/jifi.v16i2.550.

Full text

Abstract:

Medicine is a pharmaceutical product that has imperfect market characteristics. This affects affordability to the community, and therefore it is necessary for the government to regulate medicine prices. Medicine prices can be regulated in the medicine supply chain by the industry, importers, distributors and health facilities such as pharmacies, hospitals and medicine sellers. Developed and high income countries generally regulate the prices of medicines and are part of a health insurance system. In contrast with the situation in developed countries, medicine pricing regulation in developing c

APA, Harvard, Vancouver, ISO, and other styles

14

MELO, Valdete A., Bruna O. ASCEF, and Fabrizio GIANFRATE. "Italy – a study case of medicines pricing and reimbursement." Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 13, no. 2 (2022): 814. http://dx.doi.org/10.30968/rbfhss.2022.132.0814.

Full text

Abstract:

The Italian National Health Service (Servizio Sanitario Nazionale, SSN) is structured at comprehensive levels such as collective prevention and public health, cure and rehabilitation assistance, and pharmaceutical services, with the primary objective of guaranteeing universal access of all Italian citizens, on equal terms, to equitable provision of health services. Italy was used as a case study to explore their healthcare system and their economic regulation and reimbursement of pharmaceuticals. The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) is responsible for regulation re

APA, Harvard, Vancouver, ISO, and other styles

15

Moskaliuk, N. B. "Pricing of medicines as a factor influencing access to treatment." Uzhhorod National University Herald. Series: Law 1, no. 80 (2024): 211–14. http://dx.doi.org/10.24144/2307-3322.2023.80.1.31.

Full text

Abstract:

The article is devoted to the topic of access to treatment, and the issue of pricing as one of the factors that significantly affect the ability of the population to access treatment through the purchase of medicines, including expensive branded medicines that are not covered by government programs that provide such medicines free of charge. High medication costs can pose substantial barriers, particularly for those not covered by state programs, exacerbating health inequalities and hindering widespread access to necessary treatments. The article focuses on the existence of two pricing s

APA, Harvard, Vancouver, ISO, and other styles

16

Perumal-Pillay, Velisha A., Thereshen Reddy, and Fatima Suleman. "An Exploratory Study Into the Use and Pricing of Schedule Zero Medicines Post Exemption From the Single Exit Price Policy in South Africa." Global Journal of Health Science 11, no. 3 (2019): 23. http://dx.doi.org/10.5539/gjhs.v11n3p23.

Full text

Abstract:

BACKGROUND: South Africa, promulgated pricing legislation in 2004 for scheduled medicines except for, schedule zero medicines. The aim of this study was to explore the impact of schedule zero medicine exemption from the Single Exit Price policy in the private sector.  OBJECTIVES: The objectives of this study were to determine prescription pricing trends and whether any price differential for a basket of schedule zero analgesics existed across three economic areas; the number of brands available; and prices of over the counter and prescription medicines.  METHODS: The me

APA, Harvard, Vancouver, ISO, and other styles

17

BONNETT, Chris, Tania STAFINSKI, and Evelinda TRINDADE. "Medicines pricing and reimbursement in Canada." Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 13, no. 2 (2022): 811. http://dx.doi.org/10.30968/rbfhss.2022.132.0811.

Full text

Abstract:

Objective: overview of Canadian practices for regulating, financing, and funding prescription drugs. Canada provides universal health coverage for hospital and physician services but excludes universal insurance of prescription medicines. Public plans provide 42% of financing, while private drug insurance covers 35% of expenditures and over 60% of Canadians – mainly through their employer. Canada has relatively high out-of-pocket expenditure (19% of spending) and is currently the tenth largest pharmaceutical market, following Brazil. It is wrestling with inequitable coverage, low use of biosim

APA, Harvard, Vancouver, ISO, and other styles

18

David Cobb, R. "Discriminatory Pricing — If Medicines Were Cars." American Pharmacy 29, no. 9 (1989): 64. http://dx.doi.org/10.1016/s0160-3450(15)31703-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Sussex, Jon, Adrian Towse, and Nancy Devlin. "Operationalizing Value-Based Pricing of Medicines." PharmacoEconomics 31, no. 1 (2012): 1–10. http://dx.doi.org/10.1007/s40273-012-0001-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Mirzoev, Tolib, Augustina Koduah, Anna Cronin de Chavez, et al. "Implementation of medicines pricing policies in sub-Saharan Africa: protocol for a systematic review." BMJ Open 11, no. 2 (2021): e044293. http://dx.doi.org/10.1136/bmjopen-2020-044293.

Full text

Abstract:

IntroductionEnsuring universal availability and accessibility of medicines and supplies is critical for national health systems to equitably address population health needs. In sub-Saharan Africa (SSA), this is a recognised priority with multiple medicines pricing policies enacted. However, medicine prices have remained high, continue to rise and constrain their accessibility. In this systematic review, we aim to identify and analyse experiences of implementation of medicines pricing policies in SSA. Our ambition is for this evidence to contribute to improved implementation of medicines pricin

APA, Harvard, Vancouver, ISO, and other styles

21

Shen, Liang, and Yu Yan Wang. "The Limit Price Strategy Analysis of Integrated Medicine Supply Chain Based on Government Regulation." Applied Mechanics and Materials 397-400 (September 2013): 2553–56. http://dx.doi.org/10.4028/www.scientific.net/amm.397-400.2553.

Full text

Abstract:

Considering the integrated medicine supply chain, and introducing the government limit pricing and subsidy mechanism, the pricing strategy of integrated medicine supply chain was studied in this paper. And the optimal strategy in the face of market fluctuations caused by unconventional emergencies based on government regulation was given. The study shows that, under different subsidy levels, the optimal production volume, retail price and profit of the supply chain are related to production cost, market size, government regulation and government subsidy; governments limit price regulation on m

APA, Harvard, Vancouver, ISO, and other styles

22

IVAMA-BRUMMELL, Adriana M., Daniella PINGRET-KIPMAN, Priscila G. LOULY, and Rosiene R. ANDRADE. "Medicines regulation, pricing and reimbursement in Brazil." Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 13, no. 1 (2022): 769. http://dx.doi.org/10.30968/rbfhss.2022.131.0769.

Full text

Abstract:

Brazil is an upper-middle-income country with a high human development index (HDI) of 0.765 (2019). The Unique Health System (SUS) is a universal, decentralised system, free at point-of-care, although 27% of Brazilians have voluntary supplementary health insurance. Medicines are provided free-of-charge through the SUS, though there are a few exceptions where co-payment is required. Around 87% of the country’s expenditure with medicines and medical devices corresponds to out-of-pocket, highlighting the importance of price regulation. Marketing authorisation and maximum price approval are mandat

APA, Harvard, Vancouver, ISO, and other styles

23

Whitty, Jennifer A., Adem Sav, Fiona Kelly, et al. "Chronic conditions, financial burden and pharmaceutical pricing: insights from Australian consumers." Australian Health Review 38, no. 5 (2014): 589. http://dx.doi.org/10.1071/ah13190.

Full text

Abstract:

Objective To explore the perceptions of Australian consumers and carers about the financial burden associated with medicines used for the treatment of chronic conditions. Method Semi-structured interviews were undertaken with individuals (n = 97) who identified as having a chronic condition(s) (n = 70), cared for someone with a chronic condition(s) (n = 8), or both (n = 19). Participants included individuals identifying with an Aboriginal or Torres Strait Islander (n = 23) or Culturally and Linguistically Diverse (n = 19) background. Data were analysed using the constant comparison method and

APA, Harvard, Vancouver, ISO, and other styles

24

VOGLER, Sabine, and Nina ZIMMERMANN. "Improving medicines access in Brazil through collaboration in the PPRI network." Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 13, no. 2 (2022): 677. http://dx.doi.org/10.30968/rbfhss.2022.132.0677.

Full text

Abstract:

In 2020, Brazil joined Pharmaceutical Pricing and Reimbursement Information (PPRI). PPRI is a network of public authorities responsible for pharmaceutical pricing and reimbursement policies from 50, mainly European, countries. It offers a platform to its members to share information and experiences regarding pricing and reimbursement policies for medicines, and this helps improve access to affordable medicines. Information-sharing is done, among others, through network queries, country reports, meetings and webinars. Contributing to the PPRI network activities, Brazil can benefit from the poli

APA, Harvard, Vancouver, ISO, and other styles

25

Cheikh, Amine, Meryem Moutahir, Ismail Bennani, Houda Attjioui, Wadie Zerhouni, and Mustapha Bouatia. "Patients’ Perception of Morocco’s Medicine Pricing Reform and Determinants of Their Access to Health Care and Medicine." BioMed Research International 2021 (October 4, 2021): 1–9. http://dx.doi.org/10.1155/2021/6969333.

Full text

Abstract:

Background. In 2014, the Ministry of Health of Morocco implemented a reform of medicine pricing that leads to lower prices. This reform has brought about a new method of pricing medicines and a reduction in the prices of more than 1,400 of the 5,000 medicines on the market. The objective of this study was to survey patients’ perceptions of the impact of the reform on medicine prices and affordability of health care, including medicine. Methods. Between September 2017 and September 2018, 360 patients that visited a community pharmacy in four selected areas of different socioeconomic levels were

APA, Harvard, Vancouver, ISO, and other styles

26

Singh, Niharika. "Strategic Pricing of Generic Medicines in Emerging Markets: A Competitive Analysis." International Journal for Research in Management & Pharmacy 14, no. 03 (2025): 27–34. https://doi.org/10.63345/ijrmp.v14.i3.4.

Full text

Abstract:

This study examines strategic pricing methodologies for generic medicines within emerging markets, emphasizing the competitive dynamics that shape pricing decisions. Through an extensive literature review up to 2017, this manuscript synthesizes theoretical and empirical findings regarding market structures, regulatory influences, and competitive responses. Using a mixed-methods approach that combines statistical analysis with simulation research, the paper investigates how pricing strategies can be optimized to balance profitability and affordability in price-sensitive environments. Findings i

APA, Harvard, Vancouver, ISO, and other styles

27

Sholoiko, N. V., I. V. Nizhenkovska, M. M. Babenko, L. О. Hala, and N. O. Datsiuk. "Implementation of the policy of external reference pricing for medicines: a review of international approaches." Social Pharmacy in Health Care 9, no. 3 (2023): 39–49. http://dx.doi.org/10.24959/sphhcj.23.301.

Full text

Abstract:

External Reference Pricing (ERP) for medicines is one of the most widely adopted pharmaceutical pricing policies applied by countries with varying income levels for many years. The policy of ERP is aimed at minimizing drug costs and improving the accessibility of effective treatments to the population. According to experts, the inefficient implementation of the ERP system may hinder the introduction of new and innovative medicines into the country’s market. Aim. To review and summarize the scientific literature data on international approaches to implementing the policy of ERP on medicin

APA, Harvard, Vancouver, ISO, and other styles

28

Walley, Tom. "Fair pricing for medicines in the UK." Expert Review of Pharmacoeconomics & Outcomes Research 7, no. 3 (2007): 207–9. http://dx.doi.org/10.1586/14737167.7.3.207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Jommi, Claudio, Patrizio Armeni, Francesco Costa, Arianna Bertolani, and Monica Otto. "Implementation of Value-based Pricing for Medicines." Clinical Therapeutics 42, no. 1 (2020): 15–24. http://dx.doi.org/10.1016/j.clinthera.2019.11.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Hristova, Kristina, Sonja Zlatanovska, Blerina Tushi, Zorica Naumovska, and Leonid Nakov. "Management of national pricing policy of medicines." Macedonian Pharmaceutical Bulletin 68, no. 03 (2022): 471–72. http://dx.doi.org/10.33320/maced.pharm.bull.2022.68.03.226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Mobula, Linda M., Stephen Sarfo, Lynda Arthur, et al. "A novel initiative to improve access to medicines for control of non-communicable diseases in low-and middle- income countries." Gates Open Research 2 (December 24, 2019): 12. http://dx.doi.org/10.12688/gatesopenres.12798.2.

Full text

Abstract:

The global burden of non-communicable diseases (NCDs) is growing, and access to prevention and treatment strategies remain limited, especially for those in low- and middle-income countries (LMICs). Novel approaches are needed to improve access and affordability of medicines that can treat NCDs in LMICs. The Access and Affordability Initiative (AAI) is a public private partnership aiming to improve access to and availability of essential medicines for the treatment of NCDs and strengthening of health systems. Through this novel initiative a prospective cohort of patients with hypertension and d

APA, Harvard, Vancouver, ISO, and other styles

32

Mobula, Linda Meta, Stephen Sarfo, Lynda Arthur, et al. "A novel initiative to improve access to medicines for control of non-communicable diseases in low-and middle- income countries." Gates Open Research 2 (February 23, 2018): 12. http://dx.doi.org/10.12688/gatesopenres.12798.1.

Full text

Abstract:

The global burden of non-communicable diseases (NCDs) is growing, and access to prevention and treatment strategies remain limited, especially for those in low- and middle-income countries (LMICs). Novel approaches are needed to improve access and affordability of medicines that can treat NCDs in LMICs. An integrated approach including differential pricing, health systems strengthening, improved supply chain management and greater affordability can improve access to innovative branded medicines for NCDs. While differential pricing has several advantages for improving the affordability of NCD m

APA, Harvard, Vancouver, ISO, and other styles

33

Chalkidou, Kalipso, Karl Claxton, Rachel Silverman, and Prashant Yadav. "Value-based tiered pricing for universal health coverage: an idea worth revisiting." Gates Open Research 4 (February 4, 2020): 16. http://dx.doi.org/10.12688/gatesopenres.13110.1.

Full text

Abstract:

The pricing of medicines and health products ranks among the most hotly debated topics in health policy, generating controversy in richer and poorer markets alike. Creating the right pricing structure for pharmaceuticals and other healthcare products is particularly important for low- and middle-income countries, where pharmaceuticals account for a significant portion of total health expenditure; high medicine prices therefore threaten the feasibility and sustainability of nascent schemes for universal health coverage (UHC). We argue that a strategic system of value-based tiered pricing (VBTP)

APA, Harvard, Vancouver, ISO, and other styles

34

Chalkidou, Kalipso, Karl Claxton, Rachel Silverman, and Prashant Yadav. "Value-based tiered pricing for universal health coverage: an idea worth revisiting." Gates Open Research 4 (February 21, 2020): 16. http://dx.doi.org/10.12688/gatesopenres.13110.2.

Full text

Abstract:

The pricing of medicines and health products ranks among the most hotly debated topics in health policy, generating controversy in richer and poorer markets alike. Creating the right pricing structure for pharmaceuticals and other healthcare products is particularly important for low- and middle-income countries, where pharmaceuticals account for a significant portion of total health expenditure; high medicine prices therefore threaten the feasibility and sustainability of nascent schemes for universal health coverage (UHC). We argue that a strategic system of value-based tiered pricing (VBTP)

APA, Harvard, Vancouver, ISO, and other styles

35

Chalkidou, Kalipso, Karl Claxton, Rachel Silverman, and Prashant Yadav. "Value-based tiered pricing for universal health coverage: an idea worth revisiting." Gates Open Research 4 (April 24, 2020): 16. http://dx.doi.org/10.12688/gatesopenres.13110.3.

Full text

Abstract:

The pricing of medicines and health products ranks among the most hotly debated topics in health policy, generating controversy in richer and poorer markets alike. Creating the right pricing structure for pharmaceuticals and other healthcare products is particularly important for low- and middle-income countries, where pharmaceuticals account for a significant portion of total health expenditure; high medicine prices therefore threaten the feasibility and sustainability of nascent schemes for universal health coverage (UHC). We argue that a strategic system of value-based tiered pricing (VBTP)

APA, Harvard, Vancouver, ISO, and other styles

36

Tsekov, Ivo, Maria Dimitrova, and Yulian Voynikov. "Role of the EMA specific marketing authorization procedures for early access on the time to patient access in Bulgaria." Pharmacia 68, no. 2 (2021): 421–25. http://dx.doi.org/10.3897/pharmacia.68.e64931.

Full text

Abstract:

Despite the early access procedures for marketing authorization (MA) valid throughout the European Union still in the most of the Member states patient access to innovative medicines depends on cost-effectiveness, budget impact assessment and negotiations for price discount with the public payers. Retrospective analysis on the availability and time to market access of medicines authorized under the European medicines agency’s specific procedures for early access shows that despite the shortening of the time to market access after 2013, for most medicines still exceeds 365 days. This is due to

APA, Harvard, Vancouver, ISO, and other styles

37

Tsekov, Ivo, Maria Dimitrova, and Yulian Voynikov. "Role of the EMA specific marketing authorization procedures for early access on the time to patient access in Bulgaria." Pharmacia 68, no. (2) (2021): 421–25. https://doi.org/10.3897/pharmacia.68.e64931.

Full text

Abstract:

Despite the early access procedures for marketing authorization (MA) valid throughout the European Union still in the most of the Member states patient access to innovative medicines depends on cost-effectiveness, budget impact assessment and negotiations for price discount with the public payers. Retrospective analysis on the availability and time to market access of medicines authorized under the European medicines agency's specific procedures for early access shows that despite the shortening of the time to market access after 2013, for most medicines still exceeds 365 days. This is due to

APA, Harvard, Vancouver, ISO, and other styles

38

Blankart, Katharina E., and Sotiris Vandoros. "Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation." PLOS ONE 19, no. 5 (2024): e0301716. http://dx.doi.org/10.1371/journal.pone.0301716.

Full text

Abstract:

Background Healthcare systems worldwide face escalating pharmaceutical expenditures despite interventions targeting pricing and generic substitution. Existing studies often overlook unwarranted volume increases in multisource markets due to differential physician perceptions of brand name and generics. Objective This study aims to explain the outpacing of generic medicine use over brand name use in multisource markets and assess the regulatory role, specifically examining the impact of reference pricing on volume and intensity increases. Methods Analyzing German multisource prescription medici

APA, Harvard, Vancouver, ISO, and other styles

39

IVAMA-BRUMMELL, Adriana M., and Claudia S. OSORIO-DE-CASTRO. "Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil." Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 13, no. 4 (2022): 897. http://dx.doi.org/10.30968/rbfhss.2022.134.0897.

Full text

Abstract:

The special series “Pharmaceutical Pricing and Reimbursement Policies” published throughout 2022, was organised by invitation of the Brazilian Journal of Hospital Pharmacy and Health Services, to characterise medicines pricing and reimbursement in Brazil and other countries and discuss implementation, effects, gaps and opportunities for improvement. The series included an editorial, a perspective on the Pharmaceutical Pricing and Reimbursement Policies (PPRI) network and eight country case studies, namely Austria, Brazil, Greece, Canada, Italy, United Kingdom, Portugal and the United States. I

APA, Harvard, Vancouver, ISO, and other styles

40

Simoens, Steven. "Generic and biosimilar medicines: quid?" Farmeconomia. Health economics and therapeutic pathways 13, no. 3S (2012): 3–4. http://dx.doi.org/10.7175/fe.v13i3s.448.

Full text

Abstract:

Once intellectual property protection, data and marketing exclusivity of reference medicines have expired, generic medicines and biosimilar medicines can enter the off-patent market. This market entry is conditional on the approval of marketing authorization, pricing and reimbursement. Given that there tends to be confusion surrounding generic and biosimilar medicines, this Editorial introduces basic concepts related to generic and biosimilar medicines and presents the different studies and articles included in this supplement dedicated to generic and biosimilar medicines.

APA, Harvard, Vancouver, ISO, and other styles

41

IVAMA-BRUMMELL, Adriana M., Daniella PINGRET-KIPMAN, Claudia S. OSORIO-DE-CASTRO, et al. "Medicines pricing and reimbursement: innovation, competitiveness, and access." Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde 13, no. 1 (2022): 679. http://dx.doi.org/10.30968/rbfhss.2022.131.0679.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Tuck, Chloe, Abdellatif Maamri, Amy Hai Yan Chan, and Zaheer‐Ud‐Din Babar. "Editorial: Medicines pricing, access and safety in Morocco." Tropical Medicine & International Health 24, no. 3 (2019): 260–63. http://dx.doi.org/10.1111/tmi.13191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gregson, Nigel, Keiron Sparrowhawk, Josephine Mauskopf, and John Paul. "Pricing medicines: theory and practice, challenges and opportunities." Nature Reviews Drug Discovery 4, no. 2 (2005): 121–30. http://dx.doi.org/10.1038/nrd1633.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Cho, Eun, Seung-Lai Yoo, Youngju Kang, and Jong Hyuk Lee. "Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement." Regenerative Medicine 15, no. 4 (2020): 1550–60. http://dx.doi.org/10.2217/rme-2020-0035.

Full text

Abstract:

In the South Korean health technology assessment system, prices of alternative medicines, incremental cost–effectiveness ratios in pharmaco-economic evaluations and patient access improvement systems such as risk-sharing agreements are the most important factors concerning the reimbursement of regenerative medicine (RM). Research and development companies in RM should review the key features of these medicines throughout the product development cycle to increase the probability of successful reimbursement. In addition, the South Korean government should take steps to improve the system to refl

APA, Harvard, Vancouver, ISO, and other styles

45

Гончар, А. О., Н. В. Шолойко, and О. О. Комаріда. "Reimbursement of combined antihypertensive medicenes in Ukraine: aspects of inclusion and external reference pricing." Farmatsevtychnyi zhurnal, no. 6 (December 29, 2022): 53–59. http://dx.doi.org/10.32352/0367-3057.6.22.06.

Full text

Abstract:

Cardiovascular diseases (CVD), in particular arterial hypertension (AH), are the main causes of morbidity and mortality, Ukraine is on the 1st place in Europe for mortality from these diseases. Modern clinical guidelines emphasize the use of combined antihypertensive drugs, and improving the accessibility of these medicines for Ukrainian patients with hypertension is relevant. In Ukraine, at the end of 2022, there were no combined antihypertensive drugs in the List of reimbursed drugs. Therefore, there is a need to develop scientific and practical approaches to improve the «Affordable Medicine

APA, Harvard, Vancouver, ISO, and other styles

46

Lessing, Charon, Toni Ashton, and Peter Davis. "The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand." Journal of Primary Health Care 7, no. 2 (2015): 94. http://dx.doi.org/10.1071/hc15094.

Full text

Abstract:

INTRODUCTION: New Zealand's Pharmaceutical Management Agency (PHARMAC) manages the list of medicines available for prescribing with government subsidy, within a fixed annual medicines budget. PHARMAC achieves this through a mix of pricing strategies including reference pricing. In 2011, PHARMAC applied generic reference pricing to olanzapine tablets. AIM: This study sought to evaluate change in outcome measures of patients switching from originator to generic olanzapine consequent to the introduction of the policy. METHODS: A retrospective study using national health data collections was condu

APA, Harvard, Vancouver, ISO, and other styles

47

Rutter, V., P. Ocran, N. S. Osi, and B. Kebirungi. "Voluntary information and price sharing database: a scoping review of the pricing and procurement landscape across eight commonwealth member states." International Journal of Pharmacy Practice 32, Supplement_2 (2024): ii40—ii41. http://dx.doi.org/10.1093/ijpp/riae058.048.

Full text

Abstract:

Abstract Introduction Launched in 2021, the Voluntary Information and Price Sharing Database (VIPSD) aims to support procurement methods with an emphasis on price transparency, reducing costs, and sharing information on health products, suppliers, and supply chains amongst Commonwealth member states. The creation and implementation of the VIPSD has been endorsed by successive Commonwealth Ministries of Health, during their annual meetings, in 2021 and 2022. To date, there has been limited deployment of the database in member states, in part due to various pooled procurement initiatives that we

APA, Harvard, Vancouver, ISO, and other styles

48

Simoens, Steven. "Innovation through Generic Medicines: Is it Time for a Pan-European Policy?" Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 6, no. 1 (2008): 3–8. http://dx.doi.org/10.1057/jgm.2008.30.

Full text

Abstract:

This paper aims to report on the ‘Innovation through generics’ roundtable, which was convened at the European Parliament in April 2008 to discuss the role of generic medicines in stimulating innovation in the pharmaceutical sector. The roundtable identified a number of factors that hamper generic market entry in Europe and, thus, inhibit competition and innovation in the pharmaceutical sector. These factors include the decline in true innovation in the pharmaceutical sector; shortcomings in current patent and registration systems; pricing and reimbursement delays for generic medicines; greater

APA, Harvard, Vancouver, ISO, and other styles

49

No author, No author. "Economics And Pricing of Certain Segments of The Pharmaceutical Market." Journal of Complementary Medicine Research 14, no. 3 (2023): 116. http://dx.doi.org/10.5455/jcmr.2023.14.03.21.

Full text

Abstract:

Pharmaceutical innovations over the past half century have made it possible to effectively treat and prevent a wide range of diseases. These achievements were so important for modern healthcare that equal access to them is considered one of the basic human rights. This article examines the economics and pricing in certain segments of the pharmaceutical market. The authors analyze various aspects affecting drug prices and price formation mechanisms in various segments of the pharmaceutical industry. The article considers the role of pharmaceutical companies, government regulators and consumers

APA, Harvard, Vancouver, ISO, and other styles

50

Ud din Babar, Zaheer, Mohamed Izham Mohamed Ibrahim, and Nadeem Irfan Bukhari. "Medicine Utilisation and Pricing in Malaysia: The Findings of a Household Survey." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 3, no. 1 (2005): 47–61. http://dx.doi.org/10.1057/palgrave.jgm.4940098.

Full text

Abstract:

The objectives of this study were to identify the most commonly used medicines for mainly prevalent ailments and to compare retail sector prices (RSPs), public sector prices (PSPs) and international reference prices (IRPs). A convenient sampling method was employed to survey 33 households in a metropolitan city. Each family was followed once a week for eight weeks to observe their diseases and medication usage. The RSPs and PSPs for per unit doses and defined daily doses (DDDs) were compared with the IRPs. The most common ailments identified were cardiovascular and endocrine disorders followed

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!